Introduction {#S0001}
============

As biomedical research has become more data-intensive, with a higher throughput of studies, cases and assays, technology has advanced in order to create toolkits capable of analyzing, interpreting, and integrating a vast amount of data.[@CIT0001] This trend is understood within the medical sector as a paradigm change; since medical practice in essence relied on making predictions about the patient's health or disease with a limited amount of data, levering diagnosis on their experience, judgement, and personal problem-solving skills.[@CIT0002]

This change of paradigm is accompanied by a healthcare industry transformation, in which disruptive technologies have emerged to accommodate healthcare "big data" and Artificial Intelligence (AI) techniques in the biomedical sector, benefiting medical professionals and their patients.[@CIT0003] This change was also provoked by the fact that looking for solutions of complex diseases relies more on disciplines such as molecular biology, biochemistry, applied mathematics and computer science. The clearer example is looking for solutions in cancer, neurodegenerative and rare diseases, among a vast range of pathologies that currently have no solution. As the Broad Institute stated on its corporate website: "This generation has a historic opportunity and responsibility to transform medicine by using systematic approaches in the biological sciences to dramatically accelerate the understanding and treatment of disease."

In this process, the advanced interpretation of genomics through artificial intelligence and machine learning approaches plays a crucial role in the search for solutions. The use of these techniques is compulsory since the physical model that controls these processes is unknown. Figure 1Leading diseases where AI is considered. Despite the vast amount of AI literature in healthcare, the research mainly concentrates around a few disease types: cancer and neurodegenerative diseases. Reproduced from: Jiang et al. Artificial intelligence in healthcare: past, present and future. *Stroke Vascular Neurol*. 2017;2:e000101.[@CIT0004]

The conclusions of "big data" analysis through AI relating to medicine reveal two major problems:[@CIT0001] the limited amount of samples with respect to the number of control variables (genes for example), that provokes high uncertainty in medical decision-making problems. Besides, the data have an inherent level of noise that falsifies the predictions.[@CIT0002],[@CIT0005] The great heterogeneity existing in the processes that contribute to disease and health, suggests a need for tailoring medical care.[@CIT0006],[@CIT0007] Consequently, instead of making diagnostics according to classical medicine in which decisions are taken based on disease and patient's similar characteristics; precision medicine aims to shift medicine toward prevention, personalization, and precision through genomics, AI, and biotechnology. Provided how important these toolkits are in elucidating appropriate intervention targets and medical strategies for treating individual patients, AI can play an important role in the development of personalized medicines and treatments.[@CIT0007]

The definition of Personalized Medicine, according to the Precision Medicine Initiative, considers it "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person." Nowadays, there are available tools that are capable of collecting a large amount of genomic data, alongside with cutting-edge data analytics for interpretation, which aid in our understanding of genomics, disease mechanisms, and treatments ([Figure 1](#F0001){ref-type="fig"}).[@CIT0008]--[@CIT0010]

Current Trends in AI and Precision Medicine {#S0002}
===========================================

Past research trends were strongly based on evaluating medical diagnosis based on AI in contrast to human practitioners,[@CIT0011],[@CIT0012] however, AI should be deemed as an additional tool to aid in medical care; not to replace medical doctors. Later research trends intended to use AI techniques to generate more accurate methods of diagnosis based on the compilation of standardized hospital data[@CIT0013]--[@CIT0015] in order to improve the detection of diseases such as cancer or cardiovascular diseases.[@CIT0016]--[@CIT0019] However, in recent years, AI is generally used for a variety of purposes in medical care, which ranges from medical diagnosis, preventive medicine, palliative medicine to drug design and development ([Figure 2](#F0002){ref-type="fig"}).
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\end{document}$ will greatly influence the dimension of the corresponding uncertainty space. Typically, these problems are highly underdetermined. Nevertheless, it has to be pointed out that over-determined problems, where the number of data exceeds the number of model parameters also have an uncertainty space[@CIT0020],[@CIT0021] that has to be considered in the corresponding decision problem.

Preventive Medicine {#S0002-S2001}
-------------------

One of the highest potentialities of AI in precision medicine is its use in preventing diseases using techniques that could assess the risk of disease development. Cardiovascular medicine represents an area in which AI has been vastly influential, where several studies such as the one carried out by Li et al assessed the risk of heart attack utilizing an artificial neuron network.[@CIT0022] Other studies employed machine learning in order to identify the risk of developing other diseases, such as colorectal cancer,[@CIT0023] respiratory virus affinity,[@CIT0024] melanoma,[@CIT0025] mortality in smokers,[@CIT0026] depression[@CIT0001] or HIV transmission,[@CIT0027] among others.

Palliative Medicine {#S0002-S2002}
-------------------

Not only does AI have a potential use when disease strikes, but it may also be very useful in palliative applications by mitigating the disease progression. In this sense, there are remarkable studies such as the one by Dente et al[@CIT0028] which employed machine learning approaches to identify predictive profiles of pneumonia bacteria; Dagliati et al[@CIT0029] who used AI to tackle diabetes complications or in predicting focal epilepsy outcomes and ischemic stroke and thromboembolism.[@CIT0030],[@CIT0031]

Monitoring Medical Care {#S0002-S2003}
-----------------------

AI appears to be predominantly beneficial in enhancing medical doctors' work. Several works have been published to report how diagnosis performance is enhanced with the use of computer-aided detection of diseases, such as breast cancer thermography detection using deep neural networks[@CIT0032] or three-dimensional brain magnetic resonance.[@CIT0033] Other uses in medical care monitoring include the assessment of surgery tolerance or chemotherapy[@CIT0034] or metabolic disorders.[@CIT0035] Some research studies suggest that reducing the number of false positives in disease detection is possible through medical imaging,[@CIT0036],[@CIT0037] biopsies,[@CIT0038] by monitoring the disease progression[@CIT0039] and health status.[@CIT0040]

Drug Design and AI {#S0002-S2004}
------------------

Drug design is considered a very capital-intensive process. Therefore, it is necessary to re-think the current paradigm of one disease -- one target -- one drug.[@CIT0041] The current understanding of drug design is that a drug must be capable of re-establishing homeostasis; the drug hits the targets causing the disease by re-establishing the equilibrium. The reason why most compounds fail in clinical trials is because mechanisms of action are not fully understood.[@CIT0042] Also, the target-centric approach is commonly used, and it is not well connected with an advanced interpretation of the genomic data at disposal.

Bioinformatics and chemo-informatics utilize AI tools in order to rationalize the development of new compounds to target diseases. The idea in these fields is to develop multi-scale models that are capable of considering simultaneously the activity of the infection agents and the parameters of absorption, distribution, metabolism, and toxicity (known as ADMET profile).[@CIT0043],[@CIT0044] Further models utilize large datasets of chemical compounds with different composition, sizes, surface activity, in order to generate a meta-structure. This meta-structure is modeled in order to elucidate the relationships with the disease agents utilizing perturbation models.[@CIT0045] These models have been proven to be very versatile when applied to infectious diseases,[@CIT0046] immunological disorders,[@CIT0047] neurological pathologies,[@CIT0048] and cancer.[@CIT0049] Furthermore, the new approach in drug discovery is known as de novo multi-scale approach in which a drug is designed within the chemical subspace where it could be deemed beneficial. Several studies have been carried out following this paradigm in order to elucidate the relationships between the drugs and the targets, alongside the ADMET profile.[@CIT0050],[@CIT0051]

Since a target-centric approach is mainly responsible of the high attrition rates and low productivity in pharmaceutical research and development,[@CIT0052] global models such as the ones described previously are required. In addition, network system biology is of utmost importance in order to understand the impact of genetic and epigenetic factors on drug actions, where AI plays a crucial role.[@CIT0053],[@CIT0054] Figure 2Main applications of AI in healthcare. Reprdoduced from: Jiang et al. Artificial intelligence in healthcare: past, present and future. *Stroke Vascular Neurol*. 2017;2:e000101.^4^

AI for Precision Medicine: Data Quality and Relevance {#S0003}
=====================================================

Despite the recent advances in AI toolkits and their performance in medical studies, there are still some gaps and margin for improvement, suggesting that AI needs either more data or better algorithms to improve the precision medicine accuracy. In general, current trends in AI are focused on developing an algorithm, which requires large amounts of data in order to maximize the performance. This is because current ML approaches are tremendously data-hungry.[@CIT0055] It was found that vast amounts of data with simpler algorithms perform better than complex algorithms with less data. This suggests that advanced AI techniques work well only in low variability problems, which is not the case in medical care.[@CIT0056] Therefore, deep sampling approaches, as suggested by Fernández-Martínez et al,[@CIT0005],[@CIT0057],[@CIT0058] are a plausible alternative.

The relevance and accuracy of data is one of the most important factors in order to ensure that the trained model accurately represents the reality. The quality of the predictions made will never exceed the quality of the dataset utilized to train the machine-learning model.[@CIT0059] While conventional statistical methods could be used to filter the data bags; removing outliers, these methods have limited effectiveness. Their lack of effectiveness is due to the fact that these methods do not assess the quality and relevance of the data. Therefore, inaccuracy of data points may influence the trained model by introducing biases.[@CIT0060],[@CIT0061] Consequently, advanced methods in high-dimensional data analysis,[@CIT0062] sensitivity analysis and feature selection and model reduction techniques are required[@CIT0063] to tackle these problems.

As pointed out before, not only data accuracy is important, but also data relevance to the disease of interest. Many recent attempts to use Machine learning techniques rely on the use of complex machine learning tools which are trained utilizing a wide range of disease attributes, without performing an analysis in order to elucidate which of them are predictors. Carrying out this approach, the model is trained with an excess of attributes, with the associated excess of noise and inducing biases.[@CIT0064] To be more specific with regards to healthcare, the majority of precision medicine solutions have been based on large DNA sequence data,[@CIT0065] however, the majority of common diseases are believed to be caused by both epigenetic and environmental factors. Due to this, AI Genomics is the tool required to elucidate these dependencies by filtering and treating appropriately the genetic pathways, since it links DNA sequencing, environmental factors, and disease mechanisms.[@CIT0066] The major drawback of genomics in precision medicine is the lack of available data from patients that are directly related to the disease of interest.[@CIT0067]

AI in Modern Genomics: Gathering Data from Large-Scale Genomics {#S0004}
===============================================================

Application of massively parallel or Next Generation Sequencing (NGS) to large-scale genomics, which has caused an increasing level of precision and success in the medical practice, has been observed over the past 8 years.[@CIT0068] NGS is generally combined with machine learning or any other analytical approaches in order to better inform the clinical care of patients. The obtained "big data" in combination with the machine learning analytics could improve not only the clinical practice but also provide a deeper understanding of cancer and rare diseases. However, despite the opportunities that NGS and machine learning offer, there are several challenges in the clinical interpretation of data. Every small alteration in samples, NGS data, variant/mutation would require a different computational approach.

Challenges with Samples {#S0004-S2001}
-----------------------

As already pointed out in the previous section, data gathering from samples is one of the major challenges. Gathering information from tissue samples in order to provide insight into cancer or rare diseases could be harnessed by the introduction of bias from non-malignant cells (such as immune cells, stromal cells ...) which leads to a loss of signal and decreases the detection sensitivity.[@CIT0069] To avoid these issues, the Cancer Genome Atlas restricted tissues to large, high-quality, high-purity and frozen tumor samples.[@CIT0070]

Challenges Associated with NGS {#S0004-S2002}
------------------------------

Several comprehensive approaches are available in order to predict the entire range of alterations, such as whole-genome, whole-exome, and whole-transcriptome.[@CIT0071] However, these approaches typically have higher computational requirements and longer turnaround times, therefore also incurring higher costs than their more-targeted alternatives. Among bulk-NGS analyses, hundreds of thousands to millions of cells are analyzed at once, providing a global idea of a set of cells. Consequently, the majority of our knowledge of individual cells comes from the analysis of bulk-NGS, which does not address the real heterogeneity of cells. Consequently, advanced methods in high-dimensional data analysis,[@CIT0061] sensitivity analysis and feature selection and model reduction techniques are required[@CIT0062] to tackle these problems. Currently, smaller panels of hundreds of genes are utilized to infer pathologies; however, this approach is not robust enough as the discriminatory power of the genes utilized is not evaluated beforehand.[@CIT0072] By utilizing this approach, the targeted panels can be used to screen larger sets of patients who might potentially benefit from the detection of clinically actionable mutations (the most discriminatory ones). Furthermore, single-cell NGS does endeavour to address the issues of data generalization of bulk-NGS and provides information on genetic, transcriptomic and epigene for a given cell.

Challenges in Interpreting Alleles and Variants {#S0004-S2003}
-----------------------------------------------

The major limitation in the interpretation of alleles and variants is the fact that the response of allele variants whose implications, resulting in protein miss-function or miss-response to a targeted therapy, have not yet been identified.

Data sharing is of utmost importance in order to bypass this issue. It will improve the understanding and dramatically increase patients' healthcare in the treatment of cancer and rare and degenerative diseases. Genomic data are more important when data are structured and the genes and variants are linked with clinical data, including the type and treatments implemented.[@CIT0073]

AI Genomics and the Phenotype Prediction Problem {#S0005}
================================================

A ful understanding of patient's genomics is mandatory in order to design robust and efficient therapeutics. Phenotype prediction problems are highly undetermined because the number of monitored genetic probes are much higher than the number of observed samples.[@CIT0074] A robust prediction of phenotypes (diseases) is carried out through a robust sampling of the uncertainty space of the problem. Let us consider a binary classifier $\documentclass[12pt]{minimal}
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\end{document}$.[@CIT0006]--[@CIT0008]

As in any other inverse problem, the cost function topography in phenotype prediction problems is composed of several flat curvilinear valleys[@CIT0020],[@CIT0021] where the genetic signatures are located, all of them with a similar predictive accuracy of the training set. Nevertheless, in the phenotype prediction problem, the size of the high discriminatory genetic signatures varies, that is, high discriminatory genetic networks of different complexity exist, and the optimization of $\documentclass[12pt]{minimal}
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\end{document}$ is not always performed in the same space dimension. This fact complicates the sampling approach to understand the altered genetic pathways involved in the disease progression. Besides, due to the high underdetermined character of the phenotype prediction problems, their associated uncertainty space has a very high dimension, and the characterization of the involved biological pathways is very ambiguous because there exist many equivalent genetic networks that predict the phenotype with similar accuracies.[@CIT0075]--[@CIT0077] The important working hypothesis is that by sampling the uncertainty space of the phenotype prediction problems, we are able to understand the altered genetic pathways of the disease in order to use this knowledge in precision medicine for diagnosis, prognosis, and treatment optimization.

Different interesting methods were proposed by Cernea et al[@CIT0008] and successfully applied in the analysis of Triple Negative Breast Cancer metastasis, comparing the results obtained with Bayesian networks.[@CIT0078] Bayesian networks are utilized to model the genetic signatures\' distribution related to the phenotype prediction, $\documentclass[12pt]{minimal}
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\end{document}$.[@CIT0082]--[@CIT0084] Bayesian networks are computationally much more expensive than the Fisher, Holdout and Random samplers.[@CIT0006] Besides, the probabilistic parameterization of the uncertainty space is not unique. Considering all the plausible networks have to provide similar results in sampling the altered genetic pathways to other samplers. Different types of algorithms could be used in tackling precision medicine problems, such as k-Nearest-Neighbour classifier,[@CIT0085] Extreme Learning Machines,[@CIT0086] Random Forest,[@CIT0087] Support Vector Machines[@CIT0088] or Deep Neural Networks.[@CIT0089] Despite the wide range of classifiers, poor results are generally observed due to the impact of noise in data, mainly in the observed class of the samples of the training set, and the use of irrelevant features in the discrimination.[@CIT0005],[@CIT0064],[@CIT0077]

Once the altered genetic pathways are robustly sampled, the next step consists of performing an optimum selection of the therapeutics tailored according to the patient's genetic profile. This procedure aims to dramatically increase the success rate and is particularly important to understand the disease mechanisms in a given individual.

Case Study: Analysis of Metastasis and Survival in TNBC {#S0006}
=======================================================

Introduction and Methods {#S0006-S2001}
------------------------

We illustrated the importance of genomic robust sampling in precision medicine and uncertainty analysis with the analysis of the Triple Negative Breast Cancers (TNBC) phenotype. The algorithms utilized have been successfully utilized in the analysis of breast cancer and lymph node metastasis,[@CIT0008],[@CIT0090] in Sarcopenia,[@CIT0091] Multiple Sclerosis,[@CIT0092] Multiple Myeloma[@CIT0093] and Inclusion Body Myositis.[@CIT0094] More specifically, we performed a robust sampling in order to find out the altered genetic pathways by the metastasis events. To do so, we used the microarray analyzed by Jézéquel et al,[@CIT0095] which is deposited in the Gene Expression Omnibus (GEO) under the acronym GSE58812. The dataset covers data from 107 patients identified with TNBC and controlled for metastasis (44 degenerated and 63 were cured after a monitoring period of 7 years).

The comparison of different algorithms across different studies is an objective but challenging way of evaluating the performance of different methodologies. However, it is rather difficult to make comparisons, since each algorithm suffers different bias in the dataset, due to inaccuracies, lack of data or inconsistencies. Furthermore, it is more important to use the same independent set of data in order to perform a fair evaluation.

To make algorithms more robust and less sensitive to bias, the Fisher's Ratio Sampler, the Holdout Sampler and the Random Sampler are trained in different data bags and, afterwards LOOCV is carried out by consensus. That is, given a set of decision makers, the decision taken by the majority tends to be accurate when the set of decision makers tends to be infinite. That implies that during the training stage, only the best performing data bags are selected to make the blind validation.

In this case, we have used the following samplers to find the set of genes that are involved in the metastasis and survival in TNBC and compared it to the BNs ([Figure 3](#F0003){ref-type="fig"}). Fisher's Ratio Sampler: this algorithm considers the discriminatory strength of the differentially expressed genes according to its Fisher's Ratio in order to induce a prior sampling distribution of the genetic networks. The sampled networks are established using this prior distribution and their likelihood is established via an LOOCV via a k-NN classifier.Holdout Sampler: a set of random 75/25 data bag holdouts were generated from the database, where 75% of the data is used for training and 25% for validation. In our case study, we have generated 1000 holdouts. In each holdout, the genes are ranked according to the Fisher's ratio, maximizing the distance between the centers of the gene expression in each class and minimizing the intra-variance. The Fisher's ratio was combined with a previous fold-change analysis to avoid the genes with high FR and low fold-change due to small dispersions within each class.Random Sampler: this scheme selects genes and builds gene signatures of variable lengths. The algorithm shares similarities with the Fisher's Ratio Sampler, but, in this case, the prior sampling distribution is uniform within the differentially expressed genes, instead of being proportional to the Fisher's Ratio. The sampled networks\' likelihood is established via an LOOCV via a k-NN classifier.Bayesian Networks: the Bayesian Network selects genes by building genetic signatures prior to distribution by using an acyclic graph. This algorithm is used to sample the posterior distribution of the genetic signatures, $\documentclass[12pt]{minimal}
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\end{document}$.Figure 3Algorithm workflow of (**A**) Fisher's ratio sampler; (**B**) Holdout sampler; (**C**) Random sampler; (**D**) Bayesian network. Reproduced from: Cernea et al. Robust pathway sampling in phenotype prediction. Application to triple nagtive cancer. *BMC Bioinformatics*. In press.[@CIT0096]

Results and Discussion {#S0006-S2002}
----------------------

[Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"} show the 15 most frequently sampled genes by each of these algorithms. The most frequent gene, LINC00630, appears in both Fisher's ratio sampler and Random sampler algorithms, and Holdout sampler models it with a lower frequency. Other common genes appraised by all algorithms were STC1, LOC100506272, BAIAP2-AS1, LOC646482. Table 1Metastasis Prediction: List of Most-Frequently Sampled Genes by the Different Algorithms: Fisher's Ratio Sampler, Holdout Sampler, Random Sampler and Bayesian NetworkFRSHSRSBNLINC00630OTUB2LINC00630ZNF597LOC100506272STC1HIPK3ZDHHC2STC1BAIAP2-AS1CCDC116YY1BAIAP2-AS1KCNS2EXOC5SPP1ARFGAP2LOC100506272GHSRSMAD9LHX9LOC644135ZNF540SHANK1LOC646482LINC00630ATF3RBMS3CACNA1SUGT1A11557882_atPRICKLE1AC108056.1ARFGAP2220899_atPRDM11NXF3CACNA1IARFGAP2PMLGIPC3DCAF8CXADRNAV1KCNS2RP11-799D4.4AHI1MASP1DAZ1MDM2KIRREL3-AS3LOC646482UGT1A1RP11-38C18.3DRP2LOC101927735RP5-855D21.1BFSP2-AS1207743_atP4HA2EXOC5JMJD6LINC00642[^1] Table 2Survival Prediction: List of the Most-Frequently Sampled Genes by the Different AlgorithmsFRSHSRSBNLOC100506272LOC100506272ING2ZNF658EML3CHAF1A220899_atLIMK2TYRLOC400748LINC00423HAPLN2ABCB8KCNS2VSX1237969_atGYPAZNF4281561100_atLOC644135C14orf80DAZ11558494_at240923_atLILRA2LOC646482LOC100507530ANKRD541564841_atLINC00630LINC01020UBN2RP11-440I14.2233714_at206909_at234834_atLATS2TNRC18C2CD3215828_at241286_at1558494_at1566162_x\_atCACNG8LOC100506411DNASE1L3CXADRCTSCPTPN21RP11-38C18.3213777_s\_atEPS15P1UPF3APCDHB2PRKCBHCN2RGSL1DCAF8240973_s\_atP2RX5-TAX1BP3232723_atME1BTG4MMP14[^2]

We also showed the phenotype centered network obtained from Bayesian Network algorithm in [Figure 4](#F0004){ref-type="fig"}, which illustrates the directed graph formed by the 68 genes most associated with the survival phenotype. It should be noted that this graph is not unique, since there exist other plausible probabilistic parameterizations of the uncertainty space related to this phenotype prediction problem, as we have proven by using other sampling algorithms. Therefore, the conclusions for the pathway analysis and drug design obtained with just one of these parameterizations, might be biased.

The most important genes provided by the random sampler were: 1) HIPK3, which codes a serine/threonine-protein kinase, involved in transcription regulation and apoptosis. 2) CCDC116 (coiled-coil domain containing 116), mainly found in the testis and associated with risk in multiple kinds of cancers.[@CIT0097] 3) EXOC5 which is linked to peptide hormone metabolism. 4) GHSR, Growth Hormone Secretagogue Receptor which is linked to the CAMP signaling pathway. Figure 4Phenotype centered network provided by Bayesian networks in the case of survival.

Bayesian networks sampled genes are mainly related to the TGF-beta Receptor Signaling and MTOR Signaling Pathway: 1) ZNF597 encodes a zinc ﬁnger protein, involved in expression and transcription. 2) ZDHHC2 is called Palmitoyltransferase or Reduced expression associated with metastasis protein in liver.[@CIT0098] 3) YY1 is highly expressed in various types of cancers and regulates tumorigenesis through multiple pathways, such as in breast cancer.[@CIT0099]

[Tables 3](#T0003){ref-type="table"} and [4](#T0004){ref-type="table"} show the top genetic pathways inferred with the most frequently sampled genes by each algorithm. Table 3Metastasis Prediction: Pathways Sampled by Different Algorithms Ranked According to the Scoring Provided by GeneAnalyticsFRSHSScoreTop PathwaysScoreTop Pathways10.3Direct P53 Effectors11.2JNK Signaling in CD4+ TCR Pathway10.1DREAM Repression & Dynorphin Exp.9.7RhoA Signaling Pathway9.6P53 Signaling8.3ATM Pathway8.8RhoA Signaling Pathway8.1FoxO Signaling Pathway8.4P53 Pathway8.0TGF-beta Signaling Pathway**RSBNScoreTop PathwaysScoreTop Pathways**15.0DREAM Repression & Dynorphin Exp.8.1Direct P53 Effectors10.1Direct P53 Effectors8.0Proteolysis Putative SUMO-1 Pathway10.1Immune Response Role of DAP12 Receptors in NK Cells7.1Creation of C4 and C2 Activators9.9JNK Signaling in CD4+ TCR Pathway6.9TGF-beta Receptor Signaling9.8MAPK Signaling Pathway6.8MTOR Signaling Pathway[^3] Table 4Survival Prediction: Pathways Sampled by Different Algorithms Ranked According to the Scoring Provided by GeneAnalyticsFRSHSScoreTop PathwaysScoreTop Pathways9.87Integrin Pathway13.54Integrin Pathway8.96Fatty Acid Beta-oxidation (peroxisome)11.30Sweet Taste Signaling7.94DREAM Repression &Dynorphin Expression11.28DREAM Repression &Dynorphin Expression7.88Signaling Events Mediated By HDAC Class II11.13RhoA Signaling Pathway7.54Type II Interferon Signaling (IFNG)9.58Signaling Events Mediated By HDAC Class II7.19Fatty Acid Biosynthesis (KEGG)9.40Androgen Receptor Signaling Pathway6.93Fatty Acyl-CoA Biosynthesis9.39CCR5 Pathway in Macrophages**RSBNScoreTop PathwaysScoreTop Pathways**9.90TCR Signaling7.87Nucleotide-binding Domain, NLR Signaling9.79Androgen Receptor Signaling Pathway7.39Apoptosis and Autophagy9.48Presenilin-Mediated Signaling7.20C-MYC Transcriptional Repression8.57Ovarian Infertility Genes6.82NF-kB (NFkB) Pathway8.34DNA Damage Response (ATM Dependent)6.19Apoptosis Modulation and Signaling8.14Apoptotic Pathways in Synovial Fibroblasts6.13Apoptosis and Survival Caspase Cascade8.02Sweet Taste Signaling5.69Senescence and Autophagy in Cancer[^4]

The main conclusions obtained from this analysis are the following: in the Metastasis prediction most of the samplers identiﬁed the Direct P53 Effectors as the main altered pathway. Other common pathways found were the DREAM Repression and Dynorphin Expression and TGF-beta Signaling Pathway. Besides phagocytosis, a major mechanism in the immune system defense, seems to play a crucial role.In the survival prediction the integrin pathway appears to be crucial. The role of integrins in metastasis has been highlighted by Ganguly et al,[@CIT0100] among others.A robust understanding of diseases from a genomic point of view is required in order to carry out Precision Medicine.In all the cases, the pathways are involved in cancer and in immune response. Consequently, this study conﬁrms the vision that the altered pathways should be independent from the sampling approach and the classiﬁer utilized.

Application to Drug Design {#S0006-S2003}
--------------------------

The previous analysis can be used to perform drug selection and repositioning via CMAP methodologies.[@CIT0101]--[@CIT0103]

The main drugs found that can revert the genes that are deregulated in TNBC metastasis: Geldanamycin HL60 (1e-06), which is an antitumor antibiotic that inhibits the function of Heat Shock Protein 90 (HSP90), which plays important roles in the regulation of cell cycle, cell growth, cell survival, apoptosis, angiogenesis and oncogenesis. This drug has been repositioned in leukaemia cell lines (HL60).LY-294002 HL60 and MCF7 (1e-05) are potent inhibitors of Phosphatidylinositol 3-Kinases. PI3K inhibitors are effective in inhibiting tumor progression (Yang et al, 2019). LY294002 is also a BET inhibitor having both anti-inflammatories and anti-cancer properties. It has been found that the expression of the growth promoting transcription factor Myc is blocked by BET inhibitors (eg, Alderton, 2011). This drug has been repositioned in Leukaemia (HL60) and Breast Cancer cell lines.[@CIT0104]Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II. Histone deacetylase inhibitors (HDAC inhibitors, HDACi, HDIs) are chemical compounds that inhibit histone deacetylases. By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes.[@CIT0105],[@CIT0106]

Therefore, the use of deep sampling approaches combined with Connectivity Map technologies (CMAP) allows fast finding of possible compounds and the design of new drugs that maximize the mechanisms of action needed to counteract the progression of the disease. The results obtained in this case study back the introduction of AI in Precision Medicine, since the drugs obtained are also currently being tested in TNBC.[@CIT0107]

Expert Opinion {#S0007}
==============

Precision medicine is on the forefront of new paradigms in medical care. Since understanding a patient's health mechanisms is an arduous task, the use of Artificial Intelligence has become a crucial tool in understanding patients' genomics in order to generate tailored therapeutics. In this sense, Biological Invariance has arisen as a new paradigm in genomics, proteomics, metabolomics or precision medicine, which states that the analysis of genomics and potential therapeutics should be independent of the sampling methodology and the classifier utilized for their inference. Predominantly, phenotype prediction and the analysis of altered pathways have become an important discipline in drug discovery and precision medicine, that is, finding a set of genes that prospectively differentiates a specified phenotype disease with respect to a control sample. The problem is highly undetermined since the number of monitored genetic probes exceeds the number of samples; therefore, this creates ambiguity in the identification that must be solved with the aid of Artificial Intelligence and Deep sampling techniques.

Independently of the methods, robust AI schemes are necessary to integrate information from different sources and to reduce the inherent uncertainty spaces existing in this kind of analysis. Furthermore, Artificial Intelligence shall be employed to elucidate complex genetic data and all the research information available on the current and future health status of patients in order to improve patients' quality of life and reduce medical costs. This process is supposed to be, such as in the sampling of altered pathways, independent from the methodology.

We believe that any AI protocol to boost Precision Medicine should be iterative and learn from experience. Algorithms and methodologies should be kept simple and fast, since they would yield to statistically the same results and statistically with the same accuracy.

However, the utilization of AI in Precision Medicine, despite being promising, still has some limitations and challenges. Precision medicine, such as Drug Design, Palliative Medicine, Healthcare monitoring, and Preventive medicine could be considered problems of high variability. This means that ML approaches have a wide range of learning and boundary conditions in order to be trained properly. As ML is extremely data-hungry, the requirement algorithms are very complex, and its training is extremely demanding. We require the development of hybrid machine learning techniques that are capable of sampling different classifiers, boundary conditions, attributes in the training stage, while optimization of the ML architecture is carried out. In this sense, it would be interesting to develop new hybrid optimization-ML techniques, such as Stochastic Gradient Descent with Momentum[@CIT0108] or Adam optimizer.[@CIT0109]
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